Medicilon in one place
Dive Deeper
Corporate News
- Corporate News
Medicilon Celebrates Nanolattix Group’s T320 ADC Drug Approval in China, US, and Australia
- Corporate News
Global First! Medicilon Powers Tyercan’s Breakthrough Anti-Tumor Protein-Drug Tye1001 to U.S. and China IND Clearance
- Corporate News
Medicilon Supports Partner Nuoyuan Medical Equipment Co., Ltd. in Securing FDA IND Approval for Class 1 Innovation Drug Pemefolacianine
- Corporate News
A Decade of Collaboration: Medicilon Supports SinoRDA in Achieving Approval for Linaprazan Glurate
- Corporate News
Medicilon Supports Strategic Partner CGeneTech in Achieving Approval for Next-Generation DPP-4 Inhibitor
- Corporate News
Medicilon Appoints Dr. Lilly Xu as Chief Technology Officer
Medicilon Academy
- Medicilon Academy
Large Animal Models: Essential Tools in Disease Research
- Medicilon Academy
PDXO Model: A Significant Advancement in Precision Oncology
- Medicilon Academy
Did You Know That Medicilon Can Handle DMPK Studies?
- Medicilon Academy
Medicilon’s GLP-1 New Drug R&D Service
- Medicilon Academy
Antibody-oligonucleotide conjugates (AOCs) —A new wave of drug conjugates
- Medicilon Academy
The Role of the Ames Test in Predicting the Genotoxicity of Impurity Compounds in Drugs
Digital Materials
- Digital Materials
Medicilon DMPK & Bioanalysis Services (Download)
- Digital Materials
Medicilon—High Quality Integrated Drug R&D Services (Download)
- Digital Materials
